vs
Side-by-side financial comparison of Presurance Holdings, Inc. (PRHI) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
STRATA Skin Sciences, Inc. is the larger business by last-quarter revenue ($9.3M vs $5.7M, roughly 1.6× Presurance Holdings, Inc.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -369.2%, a 369.8% gap on every dollar of revenue. On growth, STRATA Skin Sciences, Inc. posted the faster year-over-year revenue change (-3.0% vs -61.4%). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs -44.7%).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
PRHI vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.7M | $9.3M |
| Net Profit | $-17.0M | $58.0K |
| Gross Margin | — | 61.8% |
| Operating Margin | -322.7% | 5.3% |
| Net Margin | -369.2% | 0.6% |
| Revenue YoY | -61.4% | -3.0% |
| Net Profit YoY | 32.9% | 101.3% |
| EPS (diluted) | $-1.40 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.7M | $9.3M | ||
| Q3 25 | $6.8M | $6.9M | ||
| Q2 25 | $16.1M | $7.7M | ||
| Q1 25 | $15.9M | $6.8M | ||
| Q4 24 | $14.7M | $9.6M | ||
| Q3 24 | $16.0M | $8.8M | ||
| Q2 24 | $17.9M | $8.4M | ||
| Q1 24 | $18.6M | $6.8M |
| Q4 25 | $-17.0M | $58.0K | ||
| Q3 25 | $-4.0M | $-1.6M | ||
| Q2 25 | $2.1M | $-2.6M | ||
| Q1 25 | $522.0K | $-2.1M | ||
| Q4 24 | $-25.4M | $-4.6M | ||
| Q3 24 | $52.8M | $-2.1M | ||
| Q2 24 | $-4.0M | $-91.0K | ||
| Q1 24 | $74.0K | $-3.4M |
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | — | 59.0% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | -322.7% | 5.3% | ||
| Q3 25 | -42.7% | -16.9% | ||
| Q2 25 | -22.6% | -30.1% | ||
| Q1 25 | -27.9% | -25.0% | ||
| Q4 24 | -177.1% | -44.7% | ||
| Q3 24 | -45.8% | -18.2% | ||
| Q2 24 | -24.3% | -5.7% | ||
| Q1 24 | 2.7% | -42.7% |
| Q4 25 | -369.2% | 0.6% | ||
| Q3 25 | -58.2% | -23.4% | ||
| Q2 25 | 12.7% | -33.6% | ||
| Q1 25 | 3.3% | -31.2% | ||
| Q4 24 | -172.4% | -47.6% | ||
| Q3 24 | 329.6% | -23.6% | ||
| Q2 24 | -22.1% | -1.1% | ||
| Q1 24 | 0.4% | -49.8% |
| Q4 25 | $-1.40 | $0.14 | ||
| Q3 25 | $-0.32 | $-0.36 | ||
| Q2 25 | $0.17 | $-0.62 | ||
| Q1 25 | $0.04 | $-0.51 | ||
| Q4 24 | $-2.08 | $-2.01 | ||
| Q3 24 | $4.32 | $-0.51 | ||
| Q2 24 | $-0.32 | $-0.03 | ||
| Q1 24 | $0.01 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.1M | $7.9M |
| Total DebtLower is stronger | $12.2M | $15.3M |
| Stockholders' EquityBook value | $9.0M | $2.9M |
| Total Assets | $239.3M | $30.5M |
| Debt / EquityLower = less leverage | 1.36× | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.1M | $7.9M | ||
| Q3 25 | $62.3M | $7.1M | ||
| Q2 25 | $58.3M | $6.0M | ||
| Q1 25 | $52.3M | $6.5M | ||
| Q4 24 | $48.8M | $7.3M | ||
| Q3 24 | $53.6M | $7.1M | ||
| Q2 24 | $33.0M | $5.5M | ||
| Q1 24 | $41.0M | $5.2M |
| Q4 25 | $12.2M | $15.3M | ||
| Q3 25 | $12.1M | $15.3M | ||
| Q2 25 | $12.1M | $15.0M | ||
| Q1 25 | $12.0M | $15.0M | ||
| Q4 24 | $11.9M | $15.0M | ||
| Q3 24 | $16.5M | $15.0M | ||
| Q2 24 | $24.8M | $15.0M | ||
| Q1 24 | $24.9M | $15.0M |
| Q4 25 | $9.0M | $2.9M | ||
| Q3 25 | $25.3M | $1.3M | ||
| Q2 25 | $28.2M | $532.0K | ||
| Q1 25 | $25.6M | $3.0M | ||
| Q4 24 | $21.5M | $5.0M | ||
| Q3 24 | $49.1M | $9.4M | ||
| Q2 24 | $-1.2M | $9.5M | ||
| Q1 24 | $2.6M | $9.4M |
| Q4 25 | $239.3M | $30.5M | ||
| Q3 25 | $285.0M | $30.7M | ||
| Q2 25 | $283.3M | $29.5M | ||
| Q1 25 | $277.1M | $33.0M | ||
| Q4 24 | $281.7M | $34.9M | ||
| Q3 24 | $299.9M | $39.4M | ||
| Q2 24 | $292.9M | $38.8M | ||
| Q1 24 | $301.1M | $39.2M |
| Q4 25 | 1.36× | 5.28× | ||
| Q3 25 | 0.48× | 11.65× | ||
| Q2 25 | 0.43× | 28.20× | ||
| Q1 25 | 0.47× | 5.04× | ||
| Q4 24 | 0.55× | 3.02× | ||
| Q3 24 | 0.34× | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | 9.75× | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-43.9M | $-239.0K |
| Free Cash FlowOCF − Capex | — | $-551.0K |
| FCF MarginFCF / Revenue | — | -5.9% |
| Capex IntensityCapex / Revenue | — | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-43.9M | $-239.0K | ||
| Q3 25 | $-681.0K | $-64.0K | ||
| Q2 25 | $-2.8M | $-1.9M | ||
| Q1 25 | $-15.3M | $-550.0K | ||
| Q4 24 | $-32.7M | $703.0K | ||
| Q3 24 | $-10.7M | $-302.0K | ||
| Q2 24 | $-10.1M | $591.0K | ||
| Q1 24 | $8.2M | $-804.0K |
| Q4 25 | — | $-551.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | — | $-749.0K | ||
| Q4 24 | — | $199.0K | ||
| Q3 24 | — | $-364.0K | ||
| Q2 24 | — | $246.0K | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | -5.9% | ||
| Q3 25 | — | -15.6% | ||
| Q2 25 | — | -26.1% | ||
| Q1 25 | — | -11.0% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | — | -4.1% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | -22.6% |
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | 14.7% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 2.9% | ||
| Q4 24 | — | 5.3% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 4.1% | ||
| Q1 24 | — | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | -1.34× | — | ||
| Q1 25 | -29.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.20× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 110.47× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRHI
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
